TCR2
Tcr2 Therapeutics Inc.
Trademark Registered: 2019-11-05
Trademark Application Details
FIFTH EXTENSION - GRANTED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 86660163 |
| Registration Number | 5903400 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Dustin R. Marlan |
| Attorney Docket Number | 48538-TM1001 |
| Law Office Assigned | M90 |
| Employee Name | YAO, GRETTA |
Timeline
| 2015-06-11 | Application Filed |
| 2016-07-12 | Published for Opposition |
| 2019-02-04 | Location: INTENT TO USE SECTION |
| 2019-02-05 | Status: Live/Pending |
| 2019-02-06 | Transaction Date |
| 2019-11-05 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  TCR2 THERAPEUTICS INC. |
| Address | 100 BINNEY STREET, SUITE 710 CAMBRIDGE DE 02142 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic proteins and therapeutic nucleic acids for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; pharmaceutical preparations for human use, namely, biotherapeutics, medicines, and therapeutics, namely, pharmaceutical polypeptides, pharmaceutical antibodies, pharmaceutical nucleic acids, polypeptide-based therapeutics, cell-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics for the treatment and prevention of cancer, inflammation and inflammatory diseases |
| GS0051 | Biotechnology and pharmaceutical products, namely, therapeutic cells, therapeutic proteins and therapeutic nucleic acids for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; pharmaceutical preparations for human use, namely, biotherapeutics, medicines, and therapeutics, namely, pharmaceutical polypeptides, pharmaceutical antibodies, pharmaceutical nucleic acids, polypeptide-based therapeutics, cell-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics for the treatment and prevention of cancer, inflammation and inflammatory diseases |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2015-06-15 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2015-06-16 | 2 NWOS I:Incoming Correspondence |
| NOTICE OF PSEUDO MARK E-MAILED | 2015-06-17 | 3 MPMK E:E-Mail |
| ASSIGNED TO EXAMINER | 2015-09-21 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2015-09-23 | 5 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2015-09-23 | 6 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2015-09-23 | 7 GNRN O:Outgoing Correspondence |
| TEAS VOLUNTARY AMENDMENT RECEIVED | 2016-03-21 | 8 PARI I:Incoming Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2016-03-21 | 9 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2016-03-31 | 10 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2016-04-07 | 11 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2016-04-07 | 12 TEME I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2016-03-21 | 13 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2016-04-07 | 14 TEME I:Incoming Correspondence |
| NON-FINAL ACTION WRITTEN | 2016-05-03 | 15 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2016-05-03 | 16 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2016-05-03 | 17 GNRN O:Outgoing Correspondence |
| EXAMINERS AMENDMENT -WRITTEN | 2016-05-28 | 18 CNEA R:Renewal |
| EXAMINERS AMENDMENT E-MAILED | 2016-05-28 | 19 GNEA O:Outgoing Correspondence |
| NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2016-05-28 | 20 GNEN O:Outgoing Correspondence |
| EXAMINER'S AMENDMENT ENTERED | 2016-05-28 | 21 XAEC I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2016-05-28 | 22 CNSA P: |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2016-06-06 | 23 PREV O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2016-06-22 | 24 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2016-07-12 | 25 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2016-07-12 | 26 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2016-09-06 | 27 NOAM E:E-Mail |
| TEAS EXTENSION RECEIVED | 2017-01-30 | 28 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2017-01-30 | 29 EXT1 S: |
| EXTENSION 1 GRANTED | 2017-01-30 | 30 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2017-02-01 | 31 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2017-07-19 | 32 EEXT I:Incoming Correspondence |
| EXTENSION 2 FILED | 2017-07-19 | 33 EXT2 S: |
| EXTENSION 2 GRANTED | 2017-07-19 | 34 EX2G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2017-07-21 | 35 EXRA E:E-Mail |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2017-12-06 | 36 COAR I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2017-12-06 | 37 CHAN I:Incoming Correspondence |
| TEAS EXTENSION RECEIVED | 2018-01-30 | 38 EEXT I:Incoming Correspondence |
| EXTENSION 3 FILED | 2018-01-30 | 39 EXT3 S: |
| EXTENSION 3 GRANTED | 2018-01-30 | 40 EX3G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-02-01 | 41 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2018-07-23 | 42 EEXT I:Incoming Correspondence |
| EXTENSION 4 FILED | 2018-07-23 | 43 EXT4 S: |
| EXTENSION 4 GRANTED | 2018-07-23 | 44 EX4G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2018-07-25 | 45 EXRA E:E-Mail |
| TEAS EXTENSION RECEIVED | 2019-01-28 | 46 EEXT I:Incoming Correspondence |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2019-01-30 | 47 ASGN I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-02-04 | 48 AITU A:Allowance for Publication |
| EXTENSION 5 FILED | 2019-01-28 | 49 EXT5 S: |
| EXTENSION 5 GRANTED | 2019-02-05 | 50 EX5G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-02-06 | 51 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2019-08-01 | 52 EISU I:Incoming Correspondence |
| USE AMENDMENT FILED | 2019-08-01 | 53 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2019-08-06 | 54 SUPC I:Incoming Correspondence |
| SU - NON-FINAL ACTION - WRITTEN | 2019-08-29 | 55 CNRT W: |
| NON-FINAL ACTION E-MAILED | 2019-08-29 | 56 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2019-08-29 | 57 GNRN O:Outgoing Correspondence |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2019-09-03 | 58 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2019-09-03 | 59 ARAA I:Incoming Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2019-09-04 | 60 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2019-09-09 | 61 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2019-09-11 | 62 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2019-09-11 | 63 TEME I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2019-10-03 | 64 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2019-10-04 | 65 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2019-11-05 | 66 R.PR A:Allowance for Publication |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 